P001 Phase 1 Study of Erlotinib, Docetaxel, and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

“…In this trial, docetaxel administered at a weekly dose of 20 mg/m 2 during concurrent RT was effective and well tolerated. Our group has also completed phase I and II studies combining radiation, docetaxel, and the anti‐epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and has demonstrated that docetaxel at 20 mg/m 2 /week is well tolerated in combination with erlotinib and radiation . It is of interest to note that a lower docetaxel dose (15 mg/m2/week) was selected in the phase III RTOG 1216 clinical trial.…”

Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers

“…In a phase I trial Savvides et al combined erlotinib with docetaxel and RT in locally advanced HNSCC (Savvides et al, 2006). The regimen consisted of weekly docetaxel (15 to 20 mg/m2) plus daily erlotinib (50 to 150 mg) with concurrent RT (70 Gy) followed by maintenance erlotinib for up to 2 years.…”

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future

“…Savvides et al [39] studied erlotinib in combination with docetaxel and RT in a phase I trial that enrolled 23 chemonaive patients with stage III-IVB SCCHN. Three dose-limiting toxicities (DLTs) were reported including a death within 30 days from last treatment in one patient and grade 3-4 mucositis; the study reported CR post-concurrent chemoradiation in 15 patients [39]. In a phase II trial which included 25 patients with stages III and IV SCCHN, Herchenhorn et al [40] combined erlotinib with cisplatin and RT.…”